The beautiful times have just started for this cmpany. With potential nasal caclcitonin sales annually of $20 million if they get their expected share of the Miacalcin market, this stock is undervalued using normal p/e multiples. If the company gets its phase 2 milestone payment around $10 million, we could easily see a $1-$1.50 move in the price. Once a stock hits the $5 target, it becomes legitamized, becomes marginable (after listing on Nasdaq) and is followed and eligible for investment by major institutions and big investors. I hope to see $7 in the near future.
News 
Market Data 
Discover 
AI
